246 related articles for article (PubMed ID: 29954776)
1. STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
Lelo A; Prip F; Harris BT; Solomon D; Berry DL; Chaldekas K; Kumar A; Simko J; Jensen JB; Bhattacharyya P; Mannion C; Kim JS; Philips G; Dyrskjøt L; Waldman T
Clin Cancer Res; 2018 Sep; 24(17):4145-4153. PubMed ID: 29954776
[No Abstract] [Full Text] [Related]
2. STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.
Taber A; Park Y; Lelo A; Prip F; Xiao J; Berry DL; Chaldekas K; Jensen JB; Philips G; Kim JS; Harris BT; Dyrskjøt L; Waldman T
Urol Oncol; 2021 Jul; 39(7):438.e1-438.e9. PubMed ID: 33712344
[TBL] [Abstract][Full Text] [Related]
3. Identification of STAG2-Mutant Bladder Cancers by Immunohistochemistry.
Park Y; Lelo A; Harris B; Berry DL; Chaldekas K; Kim JS; Waldman T
Methods Mol Biol; 2023; 2684():145-151. PubMed ID: 37410232
[TBL] [Abstract][Full Text] [Related]
4. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
[TBL] [Abstract][Full Text] [Related]
5. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.
Avgeris M; Tsilimantou A; Levis PK; Rampias T; Papadimitriou MA; Panoutsopoulou K; Stravodimos K; Scorilas A
Carcinogenesis; 2019 Aug; 40(8):965-974. PubMed ID: 30815670
[TBL] [Abstract][Full Text] [Related]
6. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
Rinaldetti S; Wirtz R; Worst TS; Hartmann A; Breyer J; Dyrskjot L; Erben P
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1701-1709. PubMed ID: 29959570
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
10. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
11. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
[TBL] [Abstract][Full Text] [Related]
12. Re: STAG2 is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
Chang SS
J Urol; 2020 Oct; 204(4):877. PubMed ID: 32716235
[No Abstract] [Full Text] [Related]
13. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
[TBL] [Abstract][Full Text] [Related]
14. Frequent truncating mutations of STAG2 in bladder cancer.
Solomon DA; Kim JS; Bondaruk J; Shariat SF; Wang ZF; Elkahloun AG; Ozawa T; Gerard J; Zhuang D; Zhang S; Navai N; Siefker-Radtke A; Phillips JJ; Robinson BD; Rubin MA; Volkmer B; Hautmann R; Küfer R; Hogendoorn PC; Netto G; Theodorescu D; James CD; Czerniak B; Miettinen M; Waldman T
Nat Genet; 2013 Dec; 45(12):1428-30. PubMed ID: 24121789
[TBL] [Abstract][Full Text] [Related]
15. ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression.
Papadimitriou MA; Avgeris M; Levis PK; Tokas T; Stravodimos K; Scorilas A
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3075-3087. PubMed ID: 31595333
[TBL] [Abstract][Full Text] [Related]
16. Stromal antigen 2 functions as a tumor suppressor in bladder cancer cells.
Wang H; Zhong J; Wu C; Liu Y; Zhang J; Zou X; Chen Y; Su J; Yang G; Zhong Y; Tang A
Oncol Rep; 2017 Aug; 38(2):917-925. PubMed ID: 28627627
[TBL] [Abstract][Full Text] [Related]
17. Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.
van Kessel KEM; van der Keur KA; Dyrskjøt L; Algaba F; Welvaart NYC; Beukers W; Segersten U; Keck B; Maurer T; Simic T; Horstmann M; Grimm MO; Hermann GG; Mogensen K; Hartmann A; Harving N; Petersen AC; Jensen JB; Junker K; Boormans JL; Real FX; Malats N; Malmström PU; Ørntoft TF; Zwarthoff EC
Clin Cancer Res; 2018 Apr; 24(7):1586-1593. PubMed ID: 29367430
[No Abstract] [Full Text] [Related]
18. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
[TBL] [Abstract][Full Text] [Related]
19. STAG2 Protein Expression in Non-muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes.
Gordon NS; Humayun-Zakaria N; Goel A; Abbotts B; Zeegers MP; Cheng KK; James ND; Arnold R; Bryan RT; Ward DG
Eur Urol Open Sci; 2022 Apr; 38():88-95. PubMed ID: 35495284
[TBL] [Abstract][Full Text] [Related]
20. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]